HIV prevalence is the total number of people living with HIV at any given point in time, whether or not they have been diagnosed. As of 2024, an estimated 40.8 million people globally were living with HIV, which translates to roughly 0.7% of adults aged 15 to 49. That single number captures the full burden of the epidemic: everyone currently infected, regardless of when they acquired the virus or whether they know their status.
Prevalence vs. Incidence: Why the Distinction Matters
Prevalence and incidence sound similar but measure very different things. Incidence counts new infections during a specific time period. If 1.3 million people were newly infected with HIV in a given year, that’s the incidence. Prevalence, by contrast, is the running total of everyone alive with the virus, including people infected decades ago. Think of incidence as the rate at which water flows into a bathtub and prevalence as the total water level.
This distinction has practical consequences. A disease can have falling incidence (fewer new infections each year) while prevalence keeps rising. That’s exactly what’s happening with HIV globally, and it’s largely a sign of progress rather than failure. When treatment keeps people alive longer, the total number living with the virus goes up even as transmission slows.
Why Global Prevalence Has Risen Since 2010
In 2010, roughly 32 million people were living with HIV worldwide. By 2024, that number climbed to 40.8 million. The primary driver is antiretroviral therapy (ART), which has transformed HIV from a near-certain death sentence into a manageable chronic condition. In Brazil, for example, life expectancy after starting treatment rose from 3.3 additional years in 1997 to 25.7 additional years by 2014. Side effects have decreased dramatically over the past two decades, meaning fewer people abandon treatment and more stay healthy for longer.
The math is straightforward: when millions of people who would have died in earlier decades now survive, prevalence rises. At the same time, new infections have declined significantly from their peak. So the climbing prevalence number reflects a population that is living with HIV rather than dying from it.
Where HIV Prevalence Is Highest
Sub-Saharan Africa carries the heaviest burden by a wide margin. Eastern and southern Africa alone account for 21.1 million people living with HIV, more than half the global total. Western and central Africa add another 5.2 million. Combined, the region is home to roughly two-thirds of all people living with HIV on the planet, despite having about 14% of the world’s population.
Within the region, prevalence varies enormously by country. Some nations in southern Africa have adult prevalence rates above 20%, while others in West Africa sit below 2%. These differences reflect decades of divergent epidemic trajectories shaped by sexual network patterns, government response times, access to testing, and cultural factors.
HIV Prevalence in the United States
An estimated 1.2 million people in the United States were living with HIV at the end of 2022. Of those, about 87% were aware of their status, a slight improvement from 86% in 2018. That remaining 13%, roughly 156,000 people, are living with undiagnosed HIV. They cannot benefit from treatment and may unknowingly transmit the virus.
Prevalence in the U.S. is not evenly distributed. It concentrates in the South, in urban areas, and among specific populations including Black and Latino men who have sex with men. These disparities reflect gaps in healthcare access, stigma, poverty, and testing availability rather than biological differences.
Gender Gaps in the Epidemic
Globally, women and girls account for a disproportionate share of HIV in sub-Saharan Africa, making up 63% of all new infections in the region. Young women aged 15 to 24 are especially vulnerable. Research from South Africa found that young women whose sexual partners were five or more years older were significantly more likely to test positive for HIV. Those older male partners were roughly twice as likely to carry high levels of the virus compared to age-similar partners, creating a cycle where infections pass from older men to younger women at elevated rates.
Outside sub-Saharan Africa, the gender pattern reverses. In most other regions, men, particularly men who have sex with men, represent the majority of people living with HIV. These contrasting patterns mean that effective prevention strategies look very different depending on where in the world you are.
What Prevalence Tells Us (and What It Doesn’t)
Prevalence is the best measure of total disease burden. It tells governments how many people need ongoing treatment, how many testing slots and clinic visits to fund, and how large the population at risk of transmitting the virus actually is. Public health agencies like the CDC use prevalence data to plan care infrastructure and allocate resources.
What prevalence cannot tell you is whether things are getting better or worse in terms of transmission. A country with rising prevalence might actually be succeeding: fewer people are dying, more are on treatment, and new infections are declining. Conversely, stable prevalence could mask a situation where new infections are replacing deaths at the same rate, which would signal failure. That’s why epidemiologists track prevalence alongside incidence and treatment coverage to get the full picture.
The 0.7% global adult prevalence rate can sound small, but it represents tens of millions of people who need lifelong medication. In the hardest-hit countries, where prevalence reaches 15 to 25% of adults, HIV shapes everything from household economics to life insurance markets to national healthcare budgets. Prevalence, in short, is the number that captures the scale of the challenge that remains even as the epidemic slowly comes under control.